{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:58:27Z","timestamp":1794340707747,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5\u2009kg m\n                    <jats:sup>\u22122<\/jats:sup>\n                    , 54% female) with obesity or overweight to examine the effects of once-daily aleniglipron escalated every 4 weeks to 45, 90 or 120\u2009mg. At week 36, the trial met its primary endpoint with a placebo-adjusted LS mean (95% confidence interval) body-weight change from baseline of \u22128.2% (\u221211.1 to \u22125.3%), \u22129.8% (\u221212.5 to \u22127.2%) and \u221211.3% (\u221213.9 to \u22128.6%) for the aleniglipron 45-, 90- and 120-mg arms, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001, all doses versus placebo), with no apparent weight-loss plateau at the end of the double-blind period. Continued weight loss was observed at the interim analysis (median treatment duration of 20 weeks) of the ongoing open-label extension. Gastrointestinal events were generally mild to moderate and decreased in frequency over time, with little to no recurrence of vomiting after reintroduction following permitted dose interruptions. Treatment-related discontinuations were 10.4% across aleniglipron arms, with no events of drug-induced liver injury. Clinically relevant weight reductions of up to 11.3% with a tolerability profile consistent with the GLP-1RA class support further development of aleniglipron for obesity treatment. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/study\/NCT06693843\" ext-link-type=\"uri\">NCT06693843<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04476-6","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:01:36Z","timestamp":1780682496000},"page":"2941-2947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania M.","family":"Jastreboff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-489X","authenticated-orcid":false,"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith L.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Connery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Civitarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blai","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ACCESS Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"4476_CR1","unstructured":"Wegovy. Prescribing Information. March 2026. https:\/\/www.novo-pi.com\/wegovy.pdf (Novo Nordisk, 2026)."},{"key":"4476_CR2","unstructured":"Foundayo. Prescribing information. April 2024. https:\/\/pi.lilly.com\/us\/foundayo-uspi.pdf (Eli Lily, 2026)."},{"key":"4476_CR3","unstructured":"Mounjaro. Prescribing information. April 2026. https:\/\/pi.lilly.com\/us\/mounjaro-uspi.pdf (Eli Lily, 2026)"},{"key":"4476_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67701-9","volume":"17","author":"F Kong","year":"2026","unstructured":"Kong, F. et al. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nat. Commun. 17, 972 (2026).","journal-title":"Nat. Commun."},{"key":"4476_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11030-025-11195-6","volume":"30","author":"A Saran","year":"2026","unstructured":"Saran, A., Raisinghani, R., Paliwal, S. & Sharma, S. GLP-1R agonists: recent advances, current gaps, and future challenges. Mol. Divers. 30, 101\u2013112 (2026).","journal-title":"Mol. Divers."},{"key":"4476_CR6","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406, 2257\u20132268 (2025).","journal-title":"Lancet"},{"key":"4476_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","volume":"24","author":"S Wharton","year":"2025","unstructured":"Wharton, S. et al. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc. Diabetol. 24, 240 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"4476_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan, B. M. et al. Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 12, 631\u2013642 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4476_CR9","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton, S. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796\u20131806 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4476_CR10","unstructured":"Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction. Draft Guidance. January 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/obesity-and-overweight-developing-drugs-and-biological-products-weight-reduction (US FDA, 2026)."},{"key":"4476_CR11","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4476_CR12","doi-asserted-by":"publisher","first-page":"100162","DOI":"10.1016\/j.obpill.2025.100162","volume":"13","author":"H Guo","year":"2025","unstructured":"Guo, H. et al. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials. Obes. Pillars. 13, 100162 (2025).","journal-title":"Obes. Pillars."},{"key":"4476_CR13","doi-asserted-by":"crossref","unstructured":"Alexander, G.C. et al. Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis. JAMA Intern. Med. 186, 567\u2013577 (2026).","DOI":"10.1001\/jamainternmed.2025.8222"},{"key":"4476_CR14","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty, R. et al. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab. Syndr. 16, 102427 (2022).","journal-title":"Diabetes Metab. Syndr."},{"key":"4476_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2504214","volume":"393","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff, A. M. et al. Once-monthly maridebart cafraglutide for the treatment of obesity \u2014 a phase 2 trial. N. Engl. J. Med. 393, 843\u2013857 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4476_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162\u2013173 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4476_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity \u2014 s phase 2 trial. N. Engl. J. Med. 389, 514\u2013526 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4476_CR18","unstructured":"Little, R.J., & Rubin, D.B. Statistical Analysis with Missing Data (John Wiley & Sons, 1987)."}],"updated-by":[{"DOI":"10.1038\/s41591-026-04532-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04476-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04476-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:59Z","timestamp":1786629719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04476-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4476"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04476-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04532-1","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04532-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R. reports clinical research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Corxel, Eli Lilly, Hanmi, Merck, Novo Nordisk, Pfizer, Regeneron, Roche, Regor, Sanofi, Structure Therapeutics and Terns; J.R. serves or has served on scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Arrowhead, Biomea Fusion, Boehringer Ingelheim, Corcept, Eccogene, Eli Lilly, Hanmi, i2O Therapeutics, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics and Terns, and has received honoraria for lectures from Eli Lilly, Novo Nordisk and Sanofi. I.L. reports received research funding (paid to institution) and\/or product from NovoNordisk, Boehringer-Ingelheim, Dexcom, Roche, Pfizer and Lilly; research related consulting fees (paid to institution) from NovoNordisk; advisory or consulting fees and\/or other support from Aadvarak Therapeutics, Abbvie, Adarx, Altasciences, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon, Bioio, Biomea, Boehringer-Ingelheim, Boston Scientific, Carmot, Corxel, Cytoki Pharma, Eli Lilly, Genentech, Janssen\/J&J, Juvena, Kailera Therapeutics, Keros Therapeutic, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Sparrow, Skye Bioscience, Source Bio, Structure Therapeutics, SUMMIT, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics and Zealand Pharma. D.R. reports having received consulting honoraria from Abbvie, Altimmune; Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot Therapeutics, Currax Pharmaceuticals, CinRx, Eli Lilly, Epitomee, Fractyl Health, i2o, ICON, Kailera, Novo Nordisk, Pfizer, PPD, Protagonist, Regor, Rhythm, Souffle, Source Bio, Structure Therapeutics, Tenvie, Viking Therapeutics, WondrHealth, Weight Watchers and Zealand Pharma. She has received stock options from Calibrate, Epitomee and Ro Health. A.M.J. conducts multicenter trials with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Rhythm Pharmaceuticals and serves on scientific advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Eli Lilly, i2o, Intellihealth\/Flyte, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche\/Genentech, Scholar Rock, Structure Therapeutics, Syntis Bio, Viking, Wave, WW International and Zealand Pharmaceuticals; academic cofounder State 4 Therapeutics. R.K. reports a position of a medical board member, advisor or consultant for Abbvie, Antag, AstraZenica, Boehringer Ingelheim, Currax, Eli Lilly, Novo Nordisk, Structure, Viking and Weight Watchers. A.A. reports participation on an advisory board or data monitoring board for Amgen, Boehringer Ingelheim, Currax, Structure Therapeutics and Regeneron; grant support to the institution from Vivus, Novo Nordisk, Phenomix Sciences and Terns Pharmaceutical; and consulting fees to the institution from Amgen, RareStone and Bausch Health. T.C.B. reports speaker or advisory relationships with BI, Eli Lily, Mannkind, and Sanfi and research funding from BI, Amgen, Dreamed, Sanofi, AstraZeneca, Eli Lily, Novo Nordisk, Sequel, Insulet, Structure, vTv, Medtronic, and Tandem Diabetes Care. M.C. reports no competing interests. F.L.H. reports no competing interests. T.S. is a primary investigator of studies sponsored by Lilly, Amgen, Novo Nordisk, Novartis, Boehringer Ingelheim, AbbVie, Reata and Vertex. L.C. reports clinical investigator activity for Eli Lilly and Structure Therapeutics. Y.L., M.L., A.B., J.B., A.C., H.Y. and B.C. are employees of Structure Therapeutics and report no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}